Previously, it has been demonstrated that serum adiponectin levels are increased in MS patients compared with healthy controls and are significantly correlated with higher activity of the disease (total ARR) and worse prognosis (PI and MSSS) [18]. Here, ADIPOQ is linked to myeloid sarcoma.